Related Experiment Videos
Pulmonary Tuberculosis among Cancer Patients Treated with Immunosuppressants: A Systematic High-risk Group Screening
Dinesh Kumar1, Shrinivasa B Marinaik2, Devi Madhavi Bhimarasetty3
1Professor, Department of Community Medicine, Dr. Rajendra Prasad Government Medical College, Kangra, Himachal Pradesh, India.
Background:
People with cancer are vulnerable and considered a high-risk group for developing pulmonary tuberculosis (PTB) as they are often treated with immunosuppressants.
Objectives:
The primary objective of the study was to screen for PTB occurrence among cancer patients. The secondary objective was to assess the risk of PTB among patients receiving immunosuppressants (I-R) compared to those not receiving immunosuppressants (I-NR).
Materials And Methods:
A sentinel surveillance was carried out among cancer patients receiving care from the oncology department of four medical colleges from January 2020 to April 2021. Descriptive analysis was done for the primary objective, whereas propensity score matching (PSM) was done to assess the secondary objective. Risk ratio (RR) was reported using logistic regression analysis.
Results:
A total of 1194 participants were assessed, and PTB was found to be 0.6% and 0.2% based on cartridge-based nucleic acid amplification test (CBNAAT) and sputum smear microscopy, respectively. PSM analysis showed a nonsignificant association between immunosuppressant use and PTB (RR: 1.3; 95% confidence interval [CI]: 0.3-6.0). PSM showed a significant association between PTB and subjective weight loss (RR: 5.3; 95% CI: 2.1-13.2), sense of fatigue (RR: 3.5; 95% CI: 1.9-6.6), and chest radiological assessment (RR: 2.8; 95% CI: 1.8-4.3).
Conclusion:
Sentinel surveillance detected PTB among cancer patients with high CBNAAT-based yield. Significantly, patients on immunosuppressants reported weight loss and fatigue that required chest radiography to screen PTB as a presumptive case.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Tuberculosis